Because CD30, in addition to its expression by tumors cells in Hodgkin lymphoma, anaplastic large cell lymphoma and human T cell leukemia virus type 1 + T cell lymphoma, is an activation marker highly upregulated by alloreactive T cells its targeting through a CAR could promote an anti-tumoral effect while at the same time eliminate recipient alloreactive T cells. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.